Clinical response observed in a phase I study in T cell lymphoma patients treated with anti-CD70 SIMPLE Antibody ARGX-110.

被引：3
|
作者：
Michot, Jean-Marie
Maerevoet, Marie
Aftimos, Philippe Georges
Rottey, Sylvie
Rolfo, Christian Diego
Offner, Fritz
Van Rompaey, Luc
Moshir, Mahan
de Haard, Hans
Silence, Karen
Pauwels, Patrick
Zwaenepoel, Karen
Awada, Ahmad
Bron, Dominique
Ribrag, Vincent
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Ctr Hosp Univ, Ottignies, Belgium
[3] Jules Bordet Canc Inst, Brussels, Belgium
[4] Ghent Univ Hosp, Heymans Inst Pharmacol, Ghent, Belgium
[5] Univ Antwerp Hosp, Phase Early Clin Trials Unit 1, Edegem, Belgium
[6] Univ Ziekenhuis Gent, Ghent, Belgium
[7] arGEN X, Zwijnaarde, Belgium
[8] arGEN X BVBA, Zwijnaarde, Belgium
[9] Univ Antwerp Hosp, Retie, Belgium
[10] UZA, Antwerp, Belgium
[11] Inst Jules Bordet, Brussels, Belgium
[12] Inst Goustave Roussy, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.7556
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7556
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma
    Gui, Lin
    Han, Xiaohong
    He, Xiaohui
    Song, Yuanyuan
    Yao, Jiarui
    Yang, Jianliang
    Liu, Peng
    Qin, Yan
    Zhang, Shuxiang
    Zhang, Weijing
    Gai, Wenlin
    Xie, Liangzhi
    Shi, Yuankai
    CHINESE JOURNAL OF CANCER RESEARCH, 2016, 28 (02) : 197 - 208
  • [22] Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma
    Lin Gui
    Xiaohong Han
    Xiaohui He
    Yuanyuan Song
    Jiarui Yao
    Jianliang Yang
    Peng Liu
    Yan Qin
    Shuxiang Zhang
    Weijing Zhang
    Wenlin Gai
    Liangzhi Xie
    Yuankai Shi
    Chinese Journal of Cancer Research, 2016, (02) : 197 - 208
  • [23] Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia
    Vey, Norbert
    Delaunay, Jacques
    Martinelli, Giovanni
    Fiedler, Walter
    Raffoux, Emmanuel
    Prebet, Thomas
    Gomez-Roca, Carlos
    Papayannidis, Cristina
    Kebenko, Maxim
    Paschka, Peter
    Christen, Randolph
    Guarin, Ernesto
    Broeske, Ann-Marie
    Baehner, Monika
    Brewster, Michael
    Walz, Antje-Christine
    Michielin, Francesca
    Runza, Valeria
    Meresse, Valerie
    Recher, Christian
    ONCOTARGET, 2016, 7 (22) : 32532 - 32542
  • [24] A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma
    Dancey, Gairin
    Violet, John
    Malaroda, Alessandra
    Green, Alan J.
    Sharma, Surinder K.
    Francis, Roslyn
    Othman, Shokri
    Parker, Sweta
    Buscombe, John
    Griffin, Natalie
    Chan, Pei-San
    Malhotra, Anmol
    Woodward, Nicholas
    Ramsay, Alan
    Ross, Philip
    Lister, T. Andrew
    Amlot, Peter
    Begent, Richard
    McNamara, Christopher
    CLINICAL CANCER RESEARCH, 2009, 15 (24) : 7701 - 7710
  • [25] European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
    Foran, JM
    Rohatiner, AZS
    Cunningham, D
    Popescu, RA
    Solal-Celigny, P
    Ghielmini, M
    Coiffier, B
    Johnson, PWM
    Gisselbrecht, C
    Reyes, F
    Radford, JA
    Bessell, EM
    Souleau, B
    Benzohra, A
    Lister, TA
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (02) : 317 - 324
  • [26] PHASE I CLINICAL TRIAL TARGETING CD20+NON-HODGKIN'S LYMPHOMA (NHL) AFTER AUTOLOGOUS STEM CELL TRANSPLANT WITH ANTI-CD3 x ANTI-CD20 BISPECIFIC ANTIBODY ARMED T CELLS
    Lum, L. G.
    Thakur, A.
    Ratanatharathorn, V
    Al-Kadhimi, Z.
    Paul, E.
    Skuba, C.
    Steel, P.
    Ayash, L.
    Abidi, M.
    Wedge, J.
    Uberti, J. P.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) : S158 - S159
  • [27] Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy
    Blum, K. A.
    Smith, M.
    Fung, H.
    Zalevsky, J.
    Combs, D.
    Ramies, D. A.
    Younes, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] A Multicenter Phase I Study of the Humanized Anti-CD19 Monoclonal Antibody, MEDI-551, in Patients with Relapsed or Refractory B-Cell Lymphoma and Multiple Myeloma
    Ogura, Michinori
    Ando, Kiyoshi
    Uike, Naokuni
    Ogawa, Yoshiaki
    Uchida, Toshiki
    Abe, Yasunobu
    Morishita, Takanobu
    Kojima, Minoru
    Choi, Ilseung
    Yagawa, Katsuro
    Yokoi, Yuki
    Okamura, Jun
    BLOOD, 2014, 124 (21)
  • [29] Clinical and immune responses in breast and hormone refractory prostate cancer patients treated with T cells armed with anti-CD3 X anti-Her2/neu bispecific antibody in a phase I clinical trial
    Davol, PA
    Gall, JM
    Young, WB
    Palushock, E
    Rathore, R
    Colvin, GA
    Lum, LG
    EXPERIMENTAL HEMATOLOGY, 2005, 33 (07) : 53 - 53
  • [30] Phase I Study of Ofatumumab, a Human Anti-CD20 Antibody, in Japanese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
    Ogura, Michinori
    Hatake, Kiyohiko
    Tobinai, Kensei
    Uchida, Toshiki
    Suzuki, Tatsuya
    Terui, Yasuhito
    Yokoyama, Masahiro
    Maruyama, Dai
    Mori, Masakazu
    Jewell, Roxanne C.
    Katsura, Koichi
    Hotta, Tomomitsu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (05) : 466 - 475
12345